BG
PCVX icon

Bellevue Group’s Vaxcyte PCVX Stock Holding History

Bellevue Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.2M Buy
+1,190,697
New +$64.6M 1.65% 22
2025
Q2 		– Sell
-11,290
Closed -$426K – 149
2025
Q1 		$426K Sell
11,290
-748
-6% -$59.8K 0.01% 121
2024
Q4 		$985K Buy
12,038
+57
+0.5% +$5.66K 0.02% 115
2024
Q3 		$1.37M Sell
11,981
-2,229
-16% -$201K 0.02% 112
2024
Q2 		$1.07M Buy
14,210
+966
+7% +$65.8K 0.02% 121
2024
Q1 		$905K Sell
13,244
-2,556
-16% -$177K 0.01% 123
2023
Q4 		$992K Sell
15,800
-14,700
-48% -$763K 0.02% 123
2023
Q3 		$1.55M Buy
30,500
+4,500
+17% +$222K 0.03% 116
2023
Q2 		$1.3M Buy
+26,000
New +$1.23M 0.02% 121

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return